ALX 0651Alternative Names: ALX-0651
Latest Information Update: 06 Mar 2012
At a glance
- Originator Ablynx
- Class Antineoplastics
- Mechanism of Action CXCR4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Mar 2012 Discontinued - Phase-I for Cancer in Europe (IV)
- 29 Jun 2011 Phase-I clinical trials in Cancer in Europe (IV)
- 28 Jul 2008 Early research in Cancer in Belgium (IV)